Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.73 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16080246 | 1.00 | DHCR7 (0.73) | DHCR7MCOLN3MEN1KMT2ATDP1 | |
| SCHEMBL841106 | 0.85 | DHCR7 (0.60) | DHCR7PTGDR2PTGDR | |
| SCHEMBL16080227 | 0.82 | DHCR7 (0.60) | DHCR7PTGDR2 | |
| SCHEMBL16080232 | 0.82 | DHCR7 (0.60) | DHCR7PTGDR2 | |
| SCHEMBL1106916 | 0.82 | DHCR7 (0.67) | DHCR7MCOLN3PTGDR2SMN1; SMN2PTGDR | |
| SCHEMBL19214946 | 0.81 | KMT2A (0.68) | MEN1KMT2ATDP1SMN1; SMN2 | |
| SCHEMBL12209246 | 0.79 | HTT (0.66) | DHCR7MEN1KMT2ATDP1HTT | |
| SCHEMBL6882681 | 0.79 | EBP (0.63) | DHCR7MCOLN3MEN1KMT2ATDP1 | |
| SCHEMBL13818486 | 0.79 | EBP (0.63) | DHCR7MCOLN3MEN1KMT2ATDP1 | |
| SCHEMBL8185779 | 0.79 | EBP (0.63) | DHCR7MCOLN3MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2752410-B1 | HETEROCYCLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY | SHIONOGI & CO (JP) | 2016-08-31 | — | — | EP | disclosed |
| US-8623903-B2 | Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2014-01-07 | — | — | US | disclosed |
| US-20120142687-A1 | INDOLECARBOXYLIC ACID DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | KUGIMIYA AKIRA (JP) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142687-A1 | INDOLECARBOXYLIC ACID DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | PTGDR, CYSLTR1, CYSLTR2 | DHCR7 760/4885MCOLN3 2077/4885MEN1 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.